Molecular determinants of selective dopaminergic vulnerability in Parkinson's disease: an update

被引:161
|
作者
Brichta, Lars [1 ]
Greengard, Paul [1 ]
机构
[1] Rockefeller Univ, Lab Mol & Cellular Neurosci, New York, NY 10065 USA
来源
关键词
Parkinson's disease; substantia nigra; ventral tegmental area; dopamine; selective vulnerability; differential vulnerability; VENTRAL TEGMENTAL AREA; SUBSTANTIA-NIGRA NEURONS; AMYOTROPHIC-LATERAL-SCLEROSIS; MITOCHONDRIAL-DNA DELETIONS; TRANSLATIONAL PROFILING APPROACH; GENE-EXPRESSION PROFILES; K-ATP CHANNELS; CNS CELL-TYPES; ALPHA-SYNUCLEIN; ALDEHYDE DEHYDROGENASE;
D O I
10.3389/fnana.2014.00152
中图分类号
R602 [外科病理学、解剖学]; R32 [人体形态学];
学科分类号
100101 ;
摘要
Numerous disorders of the central nervous system (CNS) are attributed to the selective death of distinct neuronal cell populations. Interestingly, in many of these conditions, a specific subset of neurons is extremely prone to degeneration while other, very similar neurons are less affected or even spared for many years. In Parkinson's disease (PD), the motor manifestations are primarily linked to the selective, progressive loss of dopaminergic (DA) neurons in the substantia nigra pars compacta (SNpc). In contrast, the very similar DA neurons in the ventral tegmental area (VIA) demonstrate a much lower degree of degeneration. Elucidating the molecular mechanisms underlying the phenomenon of differential DA vulnerability in PD has proven extremely challenging. Moreover, an increasing number of studies demonstrate that considerable molecular and electrophysiologic heterogeneity exists among the DA neurons within the SNpc as well as those within the VIA, adding yet another layer of complexity to the selective DA vulnerability observed in PD. The discovery of key pathways that regulate this differential susceptibility of DA neurons to degeneration holds great potential for the discovery of novel drug targets and the development of promising neuroprotective treatment strategies. This review provides an update on the molecular basis of the differential vulnerability of midbrain DA neurons in PD and highlights the most recent developments in this field.
引用
收藏
页数:16
相关论文
共 50 条
  • [41] Linking selective vulnerability to cell death mechanisms in Parkinson's disease
    Dickson, Dennis W.
    AMERICAN JOURNAL OF PATHOLOGY, 2007, 170 (01): : 16 - 19
  • [42] Calcium, cellular aging, and selective neuronal vulnerability in Parkinson's disease
    Surmeier, D. James
    Guzman, Jaime N.
    Sanchez-Padilla, Javier
    CELL CALCIUM, 2010, 47 (02) : 175 - 182
  • [43] Some molecular mechanisms of dopaminergic and glutamatergic dysfunctioning in Parkinson’s disease
    Dénes Zádori
    Levente Szalárdy
    József Toldi
    Ferenc Fülöp
    Péter Klivényi
    László Vécsei
    Journal of Neural Transmission, 2013, 120 : 673 - 681
  • [44] Some molecular mechanisms of dopaminergic and glutamatergic dysfunctioning in Parkinson's disease
    Zadori, Denes
    Szalardy, Levente
    Toldi, Jozsef
    Fueloep, Ferenc
    Klivenyi, Peter
    Vecsei, Laszlo
    JOURNAL OF NEURAL TRANSMISSION, 2013, 120 (04) : 673 - 681
  • [45] Dopaminergic Vulnerability in Parkinson Disease: The Cost of Humans' Habitual Performance
    Hernandez, Ledia F.
    Obeso, Ignacio
    Costa, Rui M.
    Redgrave, Peter
    Obeso, Jose A.
    TRENDS IN NEUROSCIENCES, 2019, 42 (06) : 375 - 383
  • [46] Dopamine compartmentalization, selective dopaminergic vulnerabilities in Parkinson's disease and therapeutic opportunities
    Uhl, George R.
    ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY, 2019, 6 (02): : 406 - 415
  • [48] Dopaminergic agonists in Parkinson's disease
    Alonso Canovas, A.
    Luquin Piudo, R.
    Garcia Ruiz-Espiga, P.
    Burguera, J. A.
    Campos Arillo, V.
    Castro, A.
    Linazasoro, G.
    Lopez del Val, J.
    Vela, L.
    Martinez Castrillo, J. C.
    NEUROLOGIA, 2014, 29 (04): : 230 - 241
  • [49] The Role of Dopamine Quinone-Modified Proteins in the Vulnerability of Dopaminergic Neurons in Parkinson's Disease
    Hastings, T. G.
    Van Laar, V.
    Dukes, A.
    Mishizen, A.
    Mortimer, A.
    Hauser, D.
    CELL TRANSPLANTATION, 2010, 19 (03) : 343 - 343
  • [50] Inhibition of vesicular monoamine transporter enhances vulnerability of dopaminergic cells: relevance to Parkinson's disease
    Choi, HJ
    Lee, SY
    Cho, Y
    Hwang, OY
    NEUROCHEMISTRY INTERNATIONAL, 2005, 46 (04) : 329 - 335